Skip to main content

Health condition · Clinically reviewed

B-cell lymphoma, from R-CHOP to CAR-T and bispecific antibodies.

A hub guide to mature B-cell non-Hodgkin lymphoma. Covers DLBCL, follicular, marginal zone, mantle cell and Burkitt disease, with today’s UK treatment ladders.

Jump to treatment
A radiographer guides a patient onto the bed of an advanced 3 Tesla MRI scanner in a London imaging suite

Why trust this guide

  • 01

    Clinically reviewed

    Written by our editorial team and reviewed by a UK haemato-oncology clinician before publication.

  • 02

    Sourced from guidance

    Checked against NICE, BSH, ESMO and NCCN guidance you can see at the end.

  • 03

    Current for 2026

    Reflects modern UK practice including CAR-T therapy, bispecific antibodies and BTK inhibitor lines for mantle cell disease.

Key facts

B-cell lymphoma at a glance.

The essentials, in plain English. What it is, the main subtypes, and how it is treated in the UK today.

  • What it is

    A group of blood cancers arising from mature B-lymphocytes. Together they make up around 85 per cent of non-Hodgkin lymphoma in the UK.

  • Most common subtype

    Diffuse large B-cell lymphoma (DLBCL) accounts for roughly 30 per cent of NHL. Aggressive but curable in around 60 to 70 per cent of patients with R-CHOP.

  • Indolent disease

    Follicular lymphoma is the commonest slow-growing form. Typically not curable, but long survival is normal with modern treatment.

  • Diagnosis

    Excision or core-needle biopsy with full immunophenotyping and molecular studies. FNA alone is not enough.

  • Staging

    PET-CT using the Lugano criteria, selective bone marrow biopsy and CNS imaging when the primary site or histology demands.

  • Where care happens

    MDT-led care across UK specialist centres including the Royal Marsden, UCLH, The Christie, King’s College Hospital, Manchester and Queen Elizabeth Hospital Birmingham.

Why this guide matters

One family of cancers, many different pathways.

B-cell lymphoma is not one disease. The subtype, stage and biology shape everything from the pace of treatment to whether the goal is cure or long-term control.

  • Aggressive can mean curable

    DLBCL, Burkitt and primary mediastinal disease grow fast but respond well to intensive combined therapy. Many patients are cured with first-line treatment.

  • Indolent needs a long game

    Follicular, marginal zone and Waldenström disease often behave like a chronic illness. Modern regimens focus on long remissions and quality of life.

  • New options change the picture

    CAR-T, bispecifics and BTK inhibitors have reshaped what is possible in relapse and now sit alongside R-CHOP, transplant and radiotherapy.

The subtypes

The main forms of B-cell lymphoma.

Subtype dictates biology, pace and treatment. Here is how a UK haemato-oncology MDT frames the map.

  • Diffuse large B-cell lymphoma (DLBCL)

    The most common NHL, around 30 per cent. Aggressive but curable in 60 to 70 per cent with R-CHOP. GCB and ABC subtypes and double-hit disease (MYC with BCL2 and/or BCL6 rearrangement) shape prognosis.

  • Follicular lymphoma

    The second commonest NHL. Indolent, usually not curable, but long survival is the norm. Classic waxing and waning course with rituximab-based regimens and maintenance.

  • Marginal zone lymphoma

    Includes gastric MALT (often linked to H. pylori), nodal marginal zone and splenic marginal zone lymphoma. Frequently indolent, sometimes cured by treating the underlying infection.

  • Mantle cell lymphoma

    Aggressive with the hallmark t(11;14) translocation and cyclin D1 overexpression. Treated with intensive chemo, autologous transplant, BTK inhibitors and, in relapse, brexucabtagene autoleucel.

  • Burkitt lymphoma

    Highly aggressive with c-MYC t(8;14) translocation. Very fast growing, high tumour lysis risk, but often curable with dose-intense regimens such as DA-EPOCH-R or CODOX-M/IVAC with CNS prophylaxis.

  • CLL and small lymphocytic lymphoma

    The commonest adult leukaemia in the UK. Overlapping biology with SLL. Modern care uses BTK inhibitors, BCL2 inhibitors and time-limited combinations. Covered in its own dedicated guide.

  • Hairy cell leukaemia

    A rare indolent B-cell malignancy with splenomegaly and cytopenias. Highly responsive to purine analogues such as cladribine.

  • Lymphoplasmacytic and Waldenström

    Characterised by an IgM paraprotein and the MYD88 L265P mutation. Managed with rituximab combinations and BTK inhibitors.

  • PMBCL, PCNSL and PTLD

    Primary mediastinal B-cell lymphoma, primary CNS lymphoma and post-transplant lymphoproliferative disease each have distinct pathways, often at specialist centres.

How the diagnosis is made

From first swollen node to a clear plan.

The steps a UK haematology or oncology team will normally follow, in order, so you know what to expect and why.

  1. 01

    Assessing

    Symptom review and examination

    Painless lymphadenopathy, drenching night sweats, unexplained fever, weight loss over 10 per cent and profound fatigue guide the initial suspicion.

  2. 02

    Assessing

    Blood work and virology

    FBC, LDH, beta-2 microglobulin, U&E, LFTs, urate, HIV, hepatitis B and C, plus EBV where relevant.

  3. 03

    Assessing

    Imaging triage

    Contrast CT of neck, chest, abdomen and pelvis to map disease and select the best node for biopsy.

  4. 04

    Confirming

    Excision or core biopsy

    Histology, immunohistochemistry (CD20, CD10, BCL2, BCL6, MYC, cyclin D1, MUM1) and FISH for MYC, BCL2 and BCL6 rearrangements.

  5. 05

    Confirming

    PET-CT for Lugano staging

    Whole-body FDG PET-CT confirms stage I to IV disease and provides the baseline for later response assessment.

  6. 06

    Confirming

    Bone marrow and CNS work-up

    Bone marrow biopsy is selective. MRI brain and CSF cytology are added for primary CNS lymphoma, testicular DLBCL and other high-risk sites.

  7. 07

    Planning

    MDT planning and fertility talk

    Haemato-oncology MDT sets the treatment plan and offers fertility preservation, cardiac baseline and vaccination review before therapy starts.

Typical timeline: first appointment to a settled treatment plan usually inside two to three weeks.

Symptoms

What B-cell lymphoma can look like.

Painless nodes and B symptoms remain the classic picture, but extranodal and mediastinal presentations are common enough to know.

  • Painless lymphadenopathy

    Firm, rubbery, non-tender nodes in the neck, axilla or groin that persist for more than three to four weeks.

  • B symptoms

    Drenching night sweats, unexplained fevers above 38 degrees and weight loss of more than 10 per cent in six months.

  • Fatigue and breathlessness

    Often from anaemia, bulky disease or marrow involvement. Deserves urgent bloods and imaging.

  • Splenomegaly and abdominal fullness

    Bulky splenic or mesenteric disease can present with early satiety, discomfort or a visible mass.

  • Extranodal presentation

    Skin, stomach, small bowel, testis, CNS or bone can be the first site. Gastric MALT is the classic example.

  • Mediastinal mass symptoms

    Primary mediastinal B-cell lymphoma can cause cough, SVC obstruction and facial swelling in young adults.

  • Neurological features

    Primary CNS lymphoma may present with focal deficits, cognitive change, seizures or cranial nerve palsies.

  • Red flag – rapid growth or SVCO

    A rapidly enlarging mass, SVC obstruction, spinal cord compression or tumour lysis features need same-day assessment.

Treatment

How B-cell lymphoma is treated in the UK.

Treatment is subtype-specific. R-CHOP anchors first-line care for DLBCL, while indolent and mantle cell disease follow their own well-worn pathways. CAR-T and bispecifics widen the options for relapse.

  • R-CHOP for DLBCL

    Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone for six cycles remains the standard curative first line for most DLBCL.

  • Pola-R-CHP first line

    Polatuzumab vedotin with R-CHP is used in fit patients with higher-risk DLBCL to improve progression-free survival over R-CHOP.

  • CAR-T cell therapy

    Axicabtagene ciloleucel, lisocabtagene maraleucel and tisagenlecleucel are options in relapsed or refractory large B-cell lymphoma at commissioned UK centres.

  • Bispecific antibodies

    Epcoritamab and glofitamab bring durable responses in heavily pre-treated DLBCL and are increasingly used after or instead of CAR-T.

  • Follicular lymphoma pathways

    Watch and wait for asymptomatic low-burden disease, then R-bendamustine, R-CHOP or R-CVP with rituximab maintenance. PI3K inhibitors, tazemetostat and CAR-T for later lines.

  • Mantle cell strategy

    Younger fit patients: R-CHOP alternating with high-dose cytarabine followed by autologous stem cell transplant and rituximab maintenance. BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib) and brexucabtagene autoleucel for relapse.

  • Burkitt lymphoma protocols

    Dose-adjusted EPOCH-R or CODOX-M/IVAC with rituximab and intrathecal CNS prophylaxis. Tumour lysis prevention is central to safe delivery.

  • MALT and localised disease

    Gastric MALT often regresses after H. pylori eradication alone. Localised marginal zone disease may be treated with involved-site radiotherapy or single-agent rituximab.

What this guide is based on

The sources behind every claim on this page.

UK national guidance and international haemato-oncology standards, current at the time of last review.

Key references

Guidelines and standards we relied on.

A quiet reminder

This guide is for information, not medical advice.

Your haematologist or oncologist knows your history, biology and imaging and can tell you which parts apply to you. If in doubt, get seen.

  • NICE. Non-Hodgkin’s lymphoma: diagnosis and management (NG52).

  • British Society for Haematology. Guidelines on the management of diffuse large B-cell lymphoma, follicular lymphoma and mantle cell lymphoma.

  • ESMO Clinical Practice Guidelines. Diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma and Burkitt lymphoma.

  • NHS England. Clinical Commissioning Policy: CAR-T cell therapy for relapsed or refractory large B-cell lymphoma.

  • Lugano Classification. Cheson BD et al. Recommendations for initial evaluation, staging and response assessment of Hodgkin and non-Hodgkin lymphoma.

Red flags

When B-cell lymphoma needs urgent attention.

These are the situations where a delay costs organ function or lives. Any one of them warrants same-day contact with the haematology team.

  • Superior vena cava obstruction

    Facial swelling, distended neck veins and breathlessness with a mediastinal mass. A same-day oncology emergency.

  • Spinal cord compression

    New back pain, leg weakness, sensory level or bladder or bowel change needs urgent MRI and steroids.

  • Tumour lysis syndrome

    High LDH, bulky or rapidly growing disease (especially Burkitt). Needs proactive hydration, allopurinol or rasburicase and close monitoring.

  • CNS involvement

    New neurological signs, cranial neuropathies or testicular DLBCL should prompt MRI brain and CSF examination.

  • Febrile neutropenia

    Fever above 38 degrees on chemotherapy with a low neutrophil count is a medical emergency requiring intravenous antibiotics within an hour.

  • Hepatitis B reactivation risk

    All patients receiving rituximab need hepatitis B screening. Core-antibody-positive patients need antiviral prophylaxis.

  • Cardiac toxicity of anthracyclines

    Doxorubicin has a cumulative dose limit. Baseline echocardiogram and long-term surveillance are standard.

  • Post-transplant lymphoproliferative disease

    New lymphadenopathy or B symptoms in a solid organ or stem cell transplant recipient needs urgent haematology referral.

  • Central line sepsis

    Fever, rigors or line-site inflammation in a patient with a Hickman or PICC line needs urgent blood cultures and empirical antibiotics.

Living with it

A serious illness, with a serious support system.

Four things that make the biggest practical difference during and after treatment. Small habits and a good team change how the whole journey feels.

A quiet reminder

The best outcomes come from asking early, not late.

New fever, new lump, new neurological sign. Ring your CNS or acute oncology line first. It is what they are there for.

  1. 01 Rhythm

    Plan life around cycles

    Chemotherapy runs in three-weekly cycles for R-CHOP. Energy dips in the first week, recovers by the third. Diaries and routines help.

  2. 02 Infection

    Guard against infection

    Hand hygiene, prompt review of fevers, PJP prophylaxis where indicated and up-to-date vaccinations under haematology guidance.

  3. 03 Late effects

    Long-term surveillance

    Cardiac, endocrine, fertility and second-cancer surveillance are shaped by the treatment received. Ask your team for a written survivorship plan.

  4. 04 Support

    Lean on the specialists

    Clinical nurse specialists, Lymphoma Action and Blood Cancer UK provide practical and emotional support alongside NHS and private care.

Frequently asked

Everything we get asked about B-cell lymphoma.

Quick answers on diagnosis, curability, watch and wait, CAR-T and fertility.

  • What is B-cell lymphoma?

    B-cell lymphoma is a group of blood cancers that arise from mature B-lymphocytes, a type of white blood cell. Together they account for around 85 per cent of non-Hodgkin lymphoma in the UK and include diffuse large B-cell lymphoma, follicular lymphoma, marginal zone lymphoma, mantle cell lymphoma, Burkitt lymphoma, chronic lymphocytic leukaemia and rarer entities such as hairy cell leukaemia and Waldenström macroglobulinaemia.

  • Is DLBCL curable?

    Diffuse large B-cell lymphoma is aggressive but curable in around 60 to 70 per cent of patients treated with R-CHOP or pola-R-CHP. For those who relapse, options include salvage chemotherapy with autologous stem cell transplant, CAR-T cell therapy and bispecific antibodies such as epcoritamab and glofitamab, and long-term remissions remain possible in second and third line.

  • Why is follicular lymphoma sometimes not treated straight away?

    Follicular lymphoma is indolent and, in asymptomatic patients with low disease burden, active surveillance (watch and wait) does not shorten survival. Treatment starts when there are B symptoms, bulky disease, cytopenias or organ compromise, and typically combines rituximab with chemotherapy followed by maintenance rituximab.

  • What happens at a lymphoma diagnostic biopsy?

    The most reliable diagnosis comes from an excision biopsy of a whole affected lymph node or a good-quality core-needle biopsy. Tissue is examined histologically and with a panel of immunohistochemistry stains and FISH probes to confirm B-cell origin and subtype, including markers such as CD20, BCL2, MYC and cyclin D1.

  • What is CAR-T therapy and who is eligible?

    CAR-T (chimeric antigen receptor T-cell) therapy re-engineers a patient’s own T cells to attack CD19-positive lymphoma. In the UK it is commissioned for selected patients with relapsed or refractory diffuse large B-cell lymphoma, mantle cell lymphoma and follicular lymphoma at specialist centres such as UCLH, King’s College Hospital, The Christie, the Royal Marsden and Manchester.

  • Can I preserve fertility before treatment?

    Yes. Every fit patient of reproductive age should be offered a fertility discussion before starting treatment. Sperm banking, oocyte or embryo cryopreservation and, where time allows, ovarian tissue preservation are widely available through NHS and private pathways and should be arranged before the first cycle of chemotherapy.

Related content

Keep reading.

Pulse Healthcare concierge

Send us your enquiry

A concierge service for UK private healthcare. We match you with the best vetted clinics and consultants in our network - they then contact you directly.

So we can match you to the right clinician close to you.

We reply to every enquiry within 24 hours (Mon–Fri). Confidential - your details are never shared outside our vetted consultant network.